Opening Session Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Deborah Collyar: What's In It for Patients?

David A. Hyman, MD, JD, on Inclusive Shared Savings

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Cost of Care

The ASCO Post Staff

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Welcome and Introduction to Vi3C

Nov

Today In Oncology

Opening Session Panel Discussion

Related Videos

Deborah Collyar: What's In It for Patients?

David A. Hyman, MD, JD, on Inclusive Shared Savings

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Welcome and Introduction to Vi3C

Metastatic Uveal Melanoma Darovasertib/Crizotinib Evaluated as First-Line Targeted Therapy

Omega-3 EPA Linked to Longer Survival After Surgery for Colorectal Cancer Liver Metastases

American Cancer Society Updates Prostate Cancer Screening Guideline

Childhood Cancers Survival Gains Reveal Progress and Persistent Disparities

Immunochemotherapy Improves Event-Free Survival in Borderline Resectable or Locally Advanced Pancreatic Cancer